Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 59 NOK 0.51%
Market Cap: 1.6B NOK
Have any thoughts about
Photocure ASA?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

18.5
Current
18
Median
13.7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
18.5
=
Enterprise Value
1.3B NOK
/
EBITDA
70.7m NOK
All Countries
Close
Market Cap EV/EBITDA
NO
Photocure ASA
OSE:PHO
1.6B NOK 18.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 459 134.4
US
Eli Lilly and Co
NYSE:LLY
747.7B USD 48
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 20.4
US
Johnson & Johnson
NYSE:JNJ
342.5B USD 11.3
US
Merck & Co Inc
NYSE:MRK
252.8B USD 10.5
CH
Roche Holding AG
SIX:ROG
216.7B CHF 10.6
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP 169.8
CH
Novartis AG
SIX:NOVN
179.3B CHF 9.7
US
Pfizer Inc
NYSE:PFE
152.2B USD 10.6
EBITDA Growth EV/EBITDA to Growth
NO
Photocure ASA
OSE:PHO
Average EV/EBITDA: 415.6
18.5
38%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.4
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.6
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.8
18%
9.4
CH
Novartis AG
SIX:NOVN
9.7
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
29.4
2-Years Forward
EV/EBITDA
16.7
3-Years Forward
EV/EBITDA
9